Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta‐analysis

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1... INTRODUCTIONHepatitis C virus (HCV) infection remains a serious public health issue worldwide. About 55‐85% of the population who have contact with HCV can develop chronic infection, which can lead to liver cirrhosis and furthermore hepatocellular carcinoma. Approximately, 130‐150 million people are affected globally and 700 000 people die each year due to HCV‐related liver complications. There are seven major genotypes, and more than 100 subtypes, of HCV from which genotype 1 is the most prevalent HCV type globally and responsible for about 60% of infections.Until recently, IFN‐based regimens were used to treat HCV, but these therapeutic regimens have been known to cause severe adverse events (AEs) and treatment discontinuation. Moreover, these regimens require weekly injection or complex dosing which can reduce the patients’ compliance. Recently, new direct‐acting antivirals (DAAs) with different mechanisms of action have been developed to provides much more efficacious and better‐tolerated therapeutic strategies than the older regimens. They can be used in combination with interferon (IFN) in shorter regimens or in combination with other DAAs in IFN‐free regimens to overcome the disadvantages of concomitant IFNs. Several IFN‐free regimens have been recommended by the World Health Organization (WHO), such as the combination of daclatasvir (DCV) and sofosbuvir (SOF) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Medical Virology Wiley

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta‐analysis

Loading next page...
 
/lp/wiley/beclabuvir-in-combination-with-asunaprevir-and-daclatasvir-for-Y9EGk8Y8pc
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0146-6615
eISSN
1096-9071
D.O.I.
10.1002/jmv.24947
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONHepatitis C virus (HCV) infection remains a serious public health issue worldwide. About 55‐85% of the population who have contact with HCV can develop chronic infection, which can lead to liver cirrhosis and furthermore hepatocellular carcinoma. Approximately, 130‐150 million people are affected globally and 700 000 people die each year due to HCV‐related liver complications. There are seven major genotypes, and more than 100 subtypes, of HCV from which genotype 1 is the most prevalent HCV type globally and responsible for about 60% of infections.Until recently, IFN‐based regimens were used to treat HCV, but these therapeutic regimens have been known to cause severe adverse events (AEs) and treatment discontinuation. Moreover, these regimens require weekly injection or complex dosing which can reduce the patients’ compliance. Recently, new direct‐acting antivirals (DAAs) with different mechanisms of action have been developed to provides much more efficacious and better‐tolerated therapeutic strategies than the older regimens. They can be used in combination with interferon (IFN) in shorter regimens or in combination with other DAAs in IFN‐free regimens to overcome the disadvantages of concomitant IFNs. Several IFN‐free regimens have been recommended by the World Health Organization (WHO), such as the combination of daclatasvir (DCV) and sofosbuvir (SOF)

Journal

Journal of Medical VirologyWiley

Published: Jan 1, 2018

Keywords: ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial